Grace Therapeutics (GRCE) Non-Current Assets (2017 - 2026)

Grace Therapeutics has disclosed Non-Current Assets across 10 years of filings, most recently posting $35.7 million for Q2 2026.

• In Q2 2026, Non-Current Assets fell 27.48% year-over-year to $35.7 million; the TTM figure through Jun 2026 stood at $183.6 million (down 6.88% YoY), while the FY2026 annual figure was $49.3 million, changed 0.01% from the prior year.
• Non-Current Assets came in at $35.7 million for Q2 2026 at Grace Therapeutics, down from $49.3 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $83.7 million in Q2 2022 to a low of $35.7 million in Q2 2026.
• Average Non-Current Assets over 5 years is $56.2 million, with a median of $49.3 million recorded in 2024.
• Year-over-year, Non-Current Assets surged 126692.42% in 2022 and sank 40.94% in 2023.
• Over 5 years, Non-Current Assets stood at $83.4 million in 2022, then tumbled by 40.87% to $49.3 million in 2023, then fell by 0.03% to $49.3 million in 2024, then decreased by 0.02% to $49.3 million in 2025, then decreased by 27.47% to $35.7 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $35.7 million in Q2 2026, $49.3 million in Q1 2026, and $49.3 million in Q4 2025.